| 1,164 | 22 | 74 |
| 下载次数 | 被引频次 | 阅读次数 |
新型冠状病毒(SARS-CoV-2)自2019年底流行至今,已进化出多个不同的亚型或分支并在全球共同传播。2020年12月14日,英国报道了一种新的SARS-CoV-2 variants of concern 202012/01(VOC 202012/01)变异株,其刺突(spike,S)蛋白累积了10个氨基酸突变,传播力增强。为分析SARS-CoV-2 VOC 202012/01变异株的全球传播与进化规律,本研究对截至到2020年12月31日的GISAID数据库中符合VOC 202012/01变异株特征的全基因组序列进行了时空分布及S蛋白进化特征分析。结果表明,VOC 202012/01变异株自2020年9月20日于英国首次出现后,在英国境内迅速蔓延,毒株数量逐月增多,并逐步扩散到全球4个大洲22个国家。在2020年9～12月传播期间,VOC 202012/01变异株的S蛋白除10个特征性位点稳定突变以外,均呈随机突变,仅有2个氨基酸突变位点存在于50条以上的序列中,行成小的分支。本文初步阐明了SARS-CoV-2 VOC 202012/01变异株的在全球早期流行中的传播与S蛋白的进化特征,为我国应对VOC 202012/01变异株的监测与防控提供科学依据。
Abstract：SARS-CoV-2 has evolved into many subtypes and branches since the end of 2019,and all these branches are simultaneously spreading around the world. On December 14,2020,a new SARS-CoV-2 variant was reported by the United Kingdom(UK),named Variant of Concern 202012/01(VOC 202012/01),which contained 10 amino acid mutations in the spike(S) protein and showed increased transmission ability. To analyze the global transmission and evolution of VOC 202012/01,whole genome sequences of VOC 202012/01 obtained from the GISAID database as of December 31,2020 were used to analyze the spatial and temporal distribution of VOC 202012/01 and the evolutionary characteristics of its S protein. The number of VOC202012/01 cases has increased monthly in the UK since it was first detected on September 20,2020. VOC202012/01 has gradually spread to 22 countries on four continents. During September to December of 2020,the S protein of VOC 202012/01 manifested as random mutation except for the stable mutations of the 10 characteristic amino acid sites. Only two amino acid mutation sites were shared by >50 uploaded sequences.Our results clarify the global early transmission of VOC 202012/01 and the evolutionary characteristics of its S protein,which provides a scientific basis for the surveillance,prevention and control of VOC 202012/01 in China.
[1]SARS-Co V-2 lineages[DB/OL].2020.Available from:https：//cov-lineages.org/lineages.html.
[2]World Health Organization.SARS-Co V-2 Variants.WHO Disease Outbreak News[OL].2020.Available from:https：//www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/.
[3]Weissman D,Alameh M G,de Silva T,Collini P,Hornsby H,Brown R,La Branche C C,Edwards R J,Sutherland L,Santra S,Mansouri K,Gobeil S,Mc Danal C,Pardi N,Hengartner N,Lin P J C,Tam Y,Shaw P A,Lewis M G,Boesler C,Sahin U,Acharya P,Haynes B F,Korber B,Montefiori D C.D614G Spike Mutation Increases SARS Co V-2Susceptibility to Neutralization[J/OL].Cell Host Microbe,2021,29(1):23-31 e24.
[4]World Health Organization.SARS-Co V-2 mink-associated variant strain-Denmark[OL].2020.Available from:https：//www.who.int/csr/don/06-november-2020-mink-associated-sars-cov2-denmark/en/.
[5]European Centre for Disease Prevention and Control.Rapid increase of a SARS-Co V-2 variant with multiple spike protein mutations observed in the United Kingdom-20 December 2020[OL].ECDC:Stockholm,2020.Available from:https：//www.ecdc.europa.eu/en/publications-data/threat-assessment-brief-rapid-increase-sars-cov-2-variant-united-kingdom#no-link.
[6]Davies N G,Barnard R C,Jarvis C I,Kucharski A J,Munday J,Pearson C A B,Russell T W,Tully D C,Abbott S,Gimma A,Waites W,Wong K L,van Zandvoort K,Eggo R M,Funk S,Jit M,Atkins K E,Edmunds W J.Estimated transmissibility and severity of novel SARS-Co V-2 Variant of Concern 202012/01 in England[OL].med Rxiv,2020.DOI:https：//doi.org/10.1101/2020.12.24.20248822.
[7]Hongyou C,Xiaoyan H,Xiang Z,Yang S,Peter H,Hui J,Xi Z,Chen F.The First Case of New Variant COVID-19 Originating in the United Kingdom Detected in a Returning Student-Shanghai Municipality,China,December 14,2020[J].China CDC Weekly,2021,3(1):1-3.
[8]World Health Organization.Weekly epidemiological update-12 January 2021[OL].2021.Available from:https：//www.who.int/publications/m/item/weekly-epidemiological-update-12-january-2021.
[9]Fanghao F,Yang S,Lipeng H,Kai N,Xiaodong S.ACase of COVID-19 Detected in a Cargo Worker at Pudong Airport-Shanghai Municipality,China,November 8,2020[J].China CDC Weekly,2020,2(47):910-911.
[10]Group C-F R,Laboratory Testing G,Yang S,Xiang Z,Xiaoyan L,Wenbo X.A Case of COVID-19-Tianjin Municipality,China,November 7,2020[J].China CDC Weekly,2020,2(46):884-885.
[11]Qun Y,Zengqiang K,Fachun J,Zhongjie L,Lijie Z,Huihui L,Xiang Z,Dianmin K,Ruqin G,Jie L.ANosocomial COVID-19 Outbreak Initiated by an Infected Dockworker at Qingdao City Port-Shandong Province,China,October,2020[J].China CDCWeekly,2020,2(43):838-840.
[12]Xiaoling T,Yang S,Kai N,Guodong W,Hongquan W,Wenbo X,Wenrui W.The Two Reemergent Confirmed COVID-19 Cases-Manzhouli City,Inner Mongolia Autonomous Region,China,November 20,2020[J].China CDC Weekly,2020,2(51):983-984.
[13]European Centre for Disease Prevention and Control.Detection of new SARS-Co V-2 variants related to mink-12 November 2020[OL].ECDC:Stockholm,2020.Available from:https：//www.ecdc.europa.eu/en/publications-data/detection-new-sars-cov-2-variants-mink#no-link.
[14]Avanzato V A,Matson M J,Seifert S N,Pryce R,Williamson B N,Anzick S L,Barbian K,Judson S D,Fischer E R,Martens C,Bowden T A,de Wit E,Riedo F X,Munster V J.Case Study:Prolonged Infectious SARS-Co V-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer[J/OL].Cell,2020,183(7):1901-1912 e1909.
[15]Starr T N,Greaney A J,Hilton S K,Ellis D,Crawford K H D,Dingens A S,Navarro M J,Bowen JE,Tortorici M A,Walls A C,King N P,Veesler D,Bloom J D.Deep Mutational Scanning of SARS-Co V-2Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding[J/OL].Cell,2020,182(5):1295-1310 e1220.
[16]Kemp S,Collier D,Datir R,Ferreira I,Gayed S,Jahun A,Hosmillo M,Rees-Spear C,Mlcochova P,Lumb I U,Roberts D J,Chandra A,Temperton N,Sharrocks K,Blane E,Briggs J,van Gils M,Smith K,Bradley J,Smith C,Doffinger R,Ceron-Gutierrez L,Barcenas-Morales G,Pollock D,Goldstein R,Smielewska A,Skittrall J,Gouliouris T,Goodfellow I,Gkrania-Klotsas E,Illingworth C,Mc Coy L,Gupta R.Neutralising antibodies in Spike mediated SARS-Co V-2 adaptation[OL].med Rxiv,2020.DOI:https：//doi.org/10.1101/2020.12.05.20241927.
[17]COG-UK.COG-UK report on SARS-Co V-2 Spike mutations of interest in the UK-15th January 2021.[OL].2021.Available from:https：//www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2_COG-UK_SARS-Co V-2-Mutations.pdf.
[18]Rees-Spear C,Muir L,Griffith S,Heaney J,Aldon Y,Snitselaar J,Thomas P,Graham C,Seow J,Lee N,Rosa A,Roustan C,Houlihan C,Sanders R,Gupta R,Cherepanov P,Stauss H,Nastouli E,Doores K,van Gils M,Mc Coy L.The impact of Spike mutations on SARS-Co V-2 neutralization[OL].bio Rxiv,2021.DOI:https：//doi.org/10.1101/2021.01.15.426849.
[19]Muik A,Wallisch A-K,S?nger B,Swanson K A,Mühl J,Chen W,Cai H,Sarkar R,Türeci?，Dormitzer P R,Sahin U.Neutralization of SARS-Co V-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera[OL].bio Rxiv,2021.DOI:https：//doi.org/10.1101/2021.01.18.426984.
[20]Mohsin H,Asif A,Fatima M,Rehman Y.Potential role of viral metagenomics as a surveillance tool for the early detection of emerging novel pathogens[OL].Arch Microbiol,2020.DOI:10.1007/s00203-020-02105-5.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.003866
中图分类号:R373
引用信息:
[1]冯晔囡,陈志肖,梦遥,等.新型冠状病毒变异株VOC 202012/01的全球早期传播与刺突蛋白进化特征分析[J].病毒学报,2021,37(02):267-273.DOI:10.13242/j.cnki.bingduxuebao.003866.
基金信息:
国家重点研发计划（项目编号：2018YFC1200305），题目：BSL-4实验室关键设备性能及风险评估与发展战略研究;国家重点研发计划（项目编号：2021YFC0863000），题目：新型冠状病毒冷链传播机制和低温消毒技术研究~~
2021-01-19
2021
2021-02-02
2021-02-09
2021
1
2021-02-08
2021-02-08
2021-02-08